查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2014840

体外诊断市场：全球市场按设备类型、技术、配置、应用和最终用户分類的预测——2026-2032年

In-Vitro Diagnostics Instrument Market by Instrument Type, Technology, Configuration, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，体外诊断市值将达到 285 亿美元，到 2026 年将成长至 309.7 亿美元，到 2032 年将达到 546.5 亿美元，复合年增长率为 9.74%。

主要市场统计数据
基准年 2025 285亿美元
预计年份：2026年 309.7亿美元
预测年份 2032 546.5亿美元
复合年增长率 (%) 9.74%

建立清晰的诊断框架，以了解检查室和即时检测环境中影响决策的检测设备分类、临床因素和技术促进因素。

体外诊断市场正处于临床需求、技术创新和不断发展的医疗服务模式的交汇点。检查室和医院对仪器的需求日益增长，这些仪器不仅需要提供更快的检测结果、更高的处理能力和更优异的分析灵敏度，还需要能够与实验室资讯系统和医院工作流程无缝整合。随着诊断流程向精准医疗和分散式检查方向转变，仪器製造商面临着在效能、成本效益和法规遵循之间取得平衡的压力。要理解这些趋势，需要对仪器分类、诊断应用以及支撑下一代检测的底层技术进行全面深入的观点。

检测技术、数位连接和医疗保健服务模式的创新如何重塑临床环境中设备的价值提案和采购决策。

多种因素共同作用，诊断设备生态系统正经历快速转型。分子诊断和免疫检测技术的进步显着提高了分析灵敏度和特异性，从而实现了疾病的早期检测和生物标记多重检测。同时，数位化和互联互通正在重新定义设备的价值提案。设备製造商如今不仅需要提供分析效能，还需要提供支援资料整合、远端监控和预测性维护的软体生态系统。这些功能有助于减少停机时间和营运风险，并使检查室即使在资源有限的环境下也能扩展其诊断能力。

本研究评估了近期贸易措施和关税压力如何促进诊断产业的供应链多元化、在地化生产决策和采购韧性。

关税和贸易政策对诊断设备供应链产生多方面影响，可能改变零件筹资策略、定价结构以及製造商的本地生产决策。在2025年之前的这段时间里，关税及相关贸易措施促使许多供应商重新考虑关键子组件和成品设备的生产地点。製造商的应对措施各不相同。一些製造商将采购转向不受关税影响地区的其他供应商，其他製造商则将部分生产本地化以降低风险，还有一些製造商则加强了供应商多元化和库存缓衝策略。

将设备分类、临床应用、底层技术、最终用户需求和配置联繫起来的详细细分见解有助于制定设计和行销策略。

仪器类型细分清楚地揭示了性能、工作流程和采购方面的考虑因素，这些因素指导着客户的决策和製造商的策略。化学分析仪通常满足大通量生物化学检验的需求，优先考虑处理能力、试剂成本效益以及与自动化系统的整合。凝血分析仪着重于凝血时间的准确性、试剂稳定性以及严格的品管流程，而血液分析仪则在细胞鑑定能力、检体处理能力和紧凑的面积之间取得平衡。免疫检测特别注重分析灵敏度、批次处理和随机存取操作之间的选择以及检验的检测菜单的可用性。微生物分析仪越来越多地整合了自动化培养测定以及快速表型和基因型抗药性检测功能。分子诊断仪器涵盖从标靶PCR平台到次世代定序系统的各种类型，需要在多重分析能力、检测时间和单次检测成本之间进行权衡。照护现场（POC​​）仪器优先考虑便携性、速度和便捷性，以支援分散式决策。

美洲、欧洲、中东和非洲以及亚太地区的法规结构、医疗保健基础设施成熟度和投资重点塑造了区域诊断市场的市场动态。

诊断设备产业的区域发展趋势受各自管理体制、医疗服务体系和投资重点的影响。在美洲，先进的医院系统、大规模参考实验室网路以及对基于更快更准确诊断的医疗保健日益重视，推动了市场需求。该地区的监管机构强调严格的临床检验和上市后监管，而采购方则优先考虑与电子健康记录和实验室资讯系统的整合。这形成了一个竞争激烈的环境，互通性、服务网络和试剂供应在采购决策中占有重要地位。

平台策略、优质服务和有针对性的创新如何决定诊断设备製造商之间的竞争。

仪器製造商之间的竞争格局日益取决于其产品和服务的整合广度、服务网络的稳健性以及支援试剂和耗材生态系统的能力。主要企业正投资于整合仪器、试剂和数位化服务的平台策略，以建立可持续的收入来源和强大的客户关係。这些策略通常辅以策略性收购，以填补其在分子检测、微生物自动化或即时检测技术等领域的产品组合空白。

为製造商和供应商提供切实可行的策略措施，以建立强大的生产系统、加强服务网络，并透过伙伴关係和数位化加速部署。

产业领导企业应采取多管齐下的策略来应对瞬息万变的诊断领域。首先，应优先考虑模组化产品设计，以实现分阶段升级并减少对单一供应商的依赖。这有助于增强供应链韧性，并透过贯穿产品生命週期的升级来提高客户维繫。其次，应投资于软体和连接功能，透过分析能力、远距离诊断以及与检查室和医院资讯系统的无缝整合来提升仪器的差异化优势。这些功能可以提高仪器的运转率，并创造附加价值服务的机会。

结合技术文献综述、监管趋势综述和专家访谈的稳健研究途径，可以对设备趋势、供应链响应和竞争动态进行多方面的分析。

本分析的研究结合了对技术文献、监管指南和行业申报文件的系统性回顾，以及对诊断、检查室管理和采购领域专家的定性访谈。仪器性能特征和技术趋势透过技术白皮书和同行评审的研究进行交叉检验，以确保测试方法和分析能力的准确性。供应炼和关税的影响则透过贸易资料、企业资讯披露以及对采购经理的访谈进行检验，以捕捉观察到的调整和策略意图。

在不断变化的诊断设备领域，製造商和买家必须整合关键挑战，以协调创新、韧性和临床效用。

诊断设备产业正处于关键的转折点，随着技术创新、变革性医疗模式和供应链重组的交汇，产品和商业重点正在重新定义。成功的设备製造商将是那些能够将卓越的分析性能与灵活的部署方案、稳健的供应链和数位化优先的服务模式相结合的企业。医疗机构和检查室网路将越来越重视那些提案可靠性、互通性和显着临床效用的整合解决方案的合作伙伴。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 体外诊断设备市场：依设备类型划分

  • 化学分析仪
  • 凝血分析仪
  • 血液检测设备
  • 免疫检测装置
  • 微生物分析仪
  • 分子诊断
  • 护理点

第九章 体外诊断设备市场：依技术划分

  • 层析法
    • 亲和层析法
    • 气相层析法
    • 离子交换层析法
    • 液相层析法
  • 流式细胞技术
    • 流式细胞技术
    • 基于图像的细胞计数方法
  • 免疫检测
    • 化学冷光
    • 酵素免疫分析法
    • 萤光免疫分析
    • 浊度免疫检测
  • 显微镜
    • 共聚焦显微镜
    • 电子显微镜
    • 光学显微镜
  • 分子
    • 杂合反应
    • 微阵列
    • 次世代定序
    • PCR
  • 光谱学
    • 萤光光谱法
    • 质谱分析
    • 紫外-可见光谱

第十章 体外诊断设备市场：依组成

  • 桌面型
  • 落地式
  • 手持式
  • 可携式的

第十一章 体外诊断设备市场：依应用领域划分

  • 自体免疫
  • 心臟标记物
  • 糖尿病
  • 感染疾病
  • 肿瘤学

第十二章 体外诊断设备市场：依最终用户划分

  • 学术研究
  • 诊断检查室
  • 医院

第十三章 体外诊断设备市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 体外诊断设备市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 体外诊断设备市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国体外诊断设备市场

第十七章：中国体外诊断设备市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioMerieux SA
  • Danaher Corporation
  • EKF GmbH
  • F. Hoffmann-La Roche Ltd
  • Hologic, Inc.
  • Illumina, Inc.
  • Mesolonghi Diagnostics
  • Ortho Clinical Diagnostics
  • PerkinElmer, Inc.
  • PHC Corporation
  • Qiagen NV
  • Roche Diagnostics
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Tulip Diagnostics（P）Ltd
Product Code: MRR-43127F7279FB

The In-Vitro Diagnostics Instrument Market was valued at USD 28.50 billion in 2025 and is projected to grow to USD 30.97 billion in 2026, with a CAGR of 9.74%, reaching USD 54.65 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 28.50 billion
Estimated Year [2026] USD 30.97 billion
Forecast Year [2032] USD 54.65 billion
CAGR (%) 9.74%

Establishing a clear diagnostic framework to understand instrument classes, clinical drivers, and technological enablers shaping laboratory and point-of-care decision making

The in-vitro diagnostics instrument landscape sits at the intersection of clinical need, technological innovation, and changing care delivery models. Laboratories and hospitals are increasingly demanding instruments that deliver faster turnaround, higher throughput, and greater analytic sensitivity while integrating seamlessly with laboratory information systems and hospital workflows. As diagnostic pathways shift toward precision medicine and decentralized testing, instrument manufacturers face pressure to balance performance with cost efficiency and regulatory compliance. Understanding these dynamics requires a holistic view of instrument classes, diagnostic applications, and the enabling technologies that underpin next-generation assays.

This introduction frames the subsequent analysis by clarifying the major instrument categories, the primary clinical applications driving demand, and the array of laboratory and hospital settings that constitute the end-user base. Chemistry Analyzer, Coagulation Analyzer, Hematology Analyzer, Immunoassay Analyzer, Microbiology Analyzer, Molecular Diagnostics, and Point of Care instruments each occupy distinct roles in diagnostic workflows, influencing procurement priorities and service models. Clinical needs across autoimmune, cardiac markers, diabetes, infectious disease, and oncology create differentiated performance requirements that feed back into instrument design and validation strategies. The technical foundations-spanning chromatography, cytometry, immunoassay, microscopy, molecular techniques, and spectrometry-determine assay sensitivity, multiplexing capability, and sample throughput.

Finally, configuration options from benchtop to floor standing to portable and handheld formats expand where tests can be performed and who performs them. This introduction lays the groundwork for a deeper exploration of the transformative shifts, tariff impacts, segmentation nuances, regional dynamics, competitive considerations, and actionable recommendations presented in the remainder of the report.

How innovation in assays, digital connectivity, and care delivery models is reshaping instrument value propositions and procurement decisions across clinical settings

The diagnostic instrument ecosystem is undergoing a period of rapid transformation driven by several converging forces. Advances in molecular and immunoassay technologies have materially improved analytic sensitivity and specificity, enabling earlier detection of disease and expanded multiplexing of biomarkers. At the same time, digitalization and connectivity are reshaping instrument value propositions: instrument manufacturers must now offer not only analytic performance but also software ecosystems that support data integration, remote monitoring, and predictive maintenance. These capabilities reduce downtime and operational risk while enabling laboratories to scale diagnostics in resource constrained environments.

Shifts in care delivery models are equally influential. The migration of certain testing from centralized laboratories to decentralized settings, including clinics and near-patient environments, has elevated the importance of compact, portable, and user-friendly configurations. Point of care instruments and handheld devices are increasingly expected to deliver laboratory-grade results with simplified workflows and minimal operator training. Concurrently, regulatory landscapes and quality management expectations have tightened, requiring manufacturers to invest in robust validation, documentation, and post-market surveillance practices.

From a commercial perspective, consolidation among diagnostic laboratories and strategic partnerships between instrumentation companies and reagent suppliers are altering procurement dynamics. These collaborations aim to create end-to-end solutions that lock in reagent consumables, drive recurring revenue, and improve lifetime customer value. Finally, sustainability considerations and total cost of ownership analyses are becoming more prominent in procurement decisions, prompting manufacturers to highlight energy efficiency, consumable reduction, and modular upgrade paths. Together, these shifts demand that industry participants rethink product roadmaps, service models, and go-to-market strategies to remain competitive and responsive to evolving healthcare needs.

Assessing how recent trade measures and tariff pressures have driven supply chain diversification, local manufacturing decisions, and procurement resilience across the diagnostic industry

Tariffs and trade policy can exert a multifaceted effect on the diagnostic instrument supply chain, altering component sourcing strategies, pricing structures, and manufacturer localization decisions. In the period leading up to 2025, a combination of tariffs and ancillary trade measures prompted many suppliers to reassess where they produce critical subassemblies and finished instruments. Manufacturers responded in diverse ways: some shifted procurement to alternate suppliers in tariff-unaffected regions, others localized portions of production to mitigate exposure, and several increased emphasis on supplier diversification and inventory buffer strategies.

These adjustments influenced product roadmaps and commercial strategies. Product teams reevaluated component standardization to reduce the number of unique parts subject to cross-border duties, while procurement organizations sought long-term agreements with geographically balanced suppliers. For healthcare providers, the tariff period increased the emphasis on transparent total cost of ownership calculations and on procurement contracts that include price protection clauses or extended support terms. Importantly, tariff-driven cost pressures also accelerated conversations about onshore service and repair capabilities, as localizing maintenance reduced dependency on imported spare parts and transnational logistics.

Regulatory and compliance teams within both supplier and buyer organizations had to account for country-specific import documentation and classification to avoid unexpected cost exposures. Simultaneously, strategic sourcing teams pursued regional manufacturing partnerships and capacity investments to lower tariff sensitivity and strengthen supply chain resilience. In sum, the tariff environment catalyzed a strategic realignment across the diagnostic instrument ecosystem, prompting greater emphasis on supplier diversification, local service infrastructure, and design choices that prioritize modularity and global manufacturability.

Deep segmentation insights linking instrument classes, clinical applications, enabling technologies, end-user needs, and configurations to inform design and go-to-market strategies

Instrument type segmentation reveals distinct performance, workflow, and procurement considerations that guide customer decisions and manufacturer strategies. Chemistry analyzers typically serve high-volume biochemical testing needs and prioritize throughput, reagent economy, and integration with automation systems. Coagulation analyzers focus on clotting time accuracy, reagent stability, and tight quality control processes, while hematology analyzers balance cellular differentiation capabilities with sample throughput and compact footprint. Immunoassay analyzers place premium value on analytical sensitivity, batch versus random access operation, and the availability of validated assay menus. Microbiology analyzers increasingly integrate automated culture reading and rapid phenotypic or genotypic resistance detection. Molecular diagnostics instruments span a spectrum from targeted PCR platforms to next-generation sequencing systems, with tradeoffs between multiplex capacity, turnaround, and cost per test. Point of care devices prioritize portability, speed, and simplicity to support decentralized decision making.

Application segmentation underscores the clinical imperatives that shape instrument adoption. Autoimmune testing requires high specificity and validated antigen panels, cardiac markers demand assays with rapid kinetics and low limits of detection, diabetes monitoring relies on both point-of-care glucometry and centralized HbA1c analyzers, infectious disease testing calls for adaptable platforms capable of rapid pathogen identification and resistance profiling, and oncology assays increasingly leverage molecular profiling and high-sensitivity immunoassays for monitoring minimal residual disease. These application needs influence validation priorities, regulatory pathways, and commercial messaging for instrument vendors.

Technological segmentation highlights how core methodologies determine analytical capability and clinical use cases. Chromatography techniques, including affinity, gas, ion exchange, and liquid chromatography, provide separation and quantitation capabilities essential for complex analyte panels. Cytometry approaches, such as flow and image cytometry, underpin cellular phenotyping and rare event detection. Immunoassay modalities-chemiluminescence, ELISA, fluorescence immunoassay, and turbidimetric immunoassay-deliver a range of sensitivity and throughput profiles. Microscopy variants from confocal to electron to light microscopy support morphological and ultrastructural analysis, while molecular methods encompassing hybridization, microarray, next-generation sequencing, and PCR enable nucleic acid-based diagnostics. Spectrometry techniques, including fluorescence spectroscopy, mass spectrometry, and UV-visible spectroscopy, offer orthogonal analytic capabilities for biomarker identification and validation.

End-user segmentation affects deployment logistics and service models. Academic research laboratories prioritize flexibility for method development and may favor modular platforms, diagnostic laboratories emphasize throughput, standardization, and compliance, and hospitals require integrated solutions that support rapid clinical decision making at scale. Configuration choices-from benchtop to floor standing to handheld and portable systems-determine where testing can be offered and influence training, maintenance, and procurement preferences. Understanding these segmentation layers in combination is essential for designing instruments, contracting service agreements, and aligning commercial strategies with customer workflows and clinical imperatives.

Regional diagnostic market dynamics shaped by regulatory frameworks, healthcare infrastructure maturity, and investment priorities across the Americas, EMEA, and Asia-Pacific

Regional dynamics in the diagnostics instrument sector are shaped by distinct regulatory regimes, healthcare delivery architectures, and investment priorities. In the Americas, demand is driven by a combination of advanced hospital systems, large reference laboratory networks, and an expanding emphasis on value-based care that rewards faster, more accurate diagnostics. Regulatory agencies in this region emphasize robust clinical validation and post-market surveillance, and purchasers prioritize integration with electronic health records and laboratory information systems. This creates a competitive environment where interoperability, service networks, and reagent availability weigh heavily in procurement decisions.

Europe, the Middle East & Africa presents a heterogeneous landscape. Western European markets are characterized by mature reimbursement frameworks, rigorous conformity assessments, and growing interest in decentralized testing models. The Middle East shows rising investment in healthcare infrastructure and a willingness to adopt cutting-edge molecular and immunoassay platforms in urban centers. In Africa, constrained resources and variable laboratory capacity drive demand for rugged, low-maintenance instruments and point-of-care solutions that can operate with limited infrastructure. Across this region, regulatory harmonization efforts and public-private partnerships influence how new technologies are evaluated and deployed.

Asia-Pacific encompasses diverse health systems ranging from highly advanced, technology-savvy markets to rapidly developing public health programs. Several economies in this region are investing heavily in genomics, personalized medicine, and domestic manufacturing capabilities, which has implications for both competitive dynamics and local supply chain development. The regulatory environment varies significantly, with some jurisdictions streamlining approvals for high-impact diagnostics and others maintaining stringent local evidence requirements. In sum, regional strategies must be tailored to reflect differences in procurement behavior, regulatory expectations, infrastructure maturity, and the prevalence of targeted disease burdens.

How platform strategies, service excellence, and targeted innovation determine competitive advantage among diagnostic instrument manufacturers

Competitive dynamics among instrument manufacturers are increasingly defined by the breadth of their integrated offerings, strength of their service networks, and ability to support reagent and consumable ecosystems. Leading firms are investing in platformization strategies that lock together instruments, reagents, and digital services to create recurring revenue streams and sticky customer relationships. These strategies are often complemented by strategic acquisitions that fill portfolio gaps in molecular assays, microbiology automation, or point-of-care technologies.

Innovation and intellectual property remain critical differentiators. Companies that can demonstrate robust clinical evidence for new assay modalities, proprietary reagent chemistries, or enabled analytics gain an advantage in both hospital and reference laboratory purchasing decisions. At the same time, nimble smaller firms and specialty vendors continue to drive disruptive change by focusing on niche applications, rapid regulatory approval cycles, and partnerships with academic centers for early validation studies.

Service and support capabilities are another competitive battleground. Organizations that provide rapid onsite maintenance, predictive servicing enabled by device telemetry, and flexible financing options tend to secure long-term contracts with large laboratory networks. Moreover, distribution partnerships and localized manufacturing arrangements help firms overcome tariff and logistics challenges while tailoring offerings to regional clinical needs. Ultimately, market success requires a balanced approach that blends innovation, commercial agility, and an unwavering focus on customer uptime and workflow integration.

Practical strategic moves for manufacturers and suppliers to build resilient production, strengthen service networks, and accelerate adoption through partnerships and digital enablement

Industry leaders should adopt a multi-pronged approach to navigate the evolving diagnostic environment. First, prioritize modular product designs that enable incremental upgrades and reduce dependency on single-source components; this enhances supply chain resilience and supports customer retention through lifecycle upgrades. Second, invest in software and connectivity capabilities that differentiate instruments through analytics, remote diagnostics, and seamless integration with laboratory and hospital information systems. These capabilities improve instrument uptime and create opportunities for value-added services.

Third, deepen collaboration with reagent and assay developers to create validated, co-branded solutions that accelerate uptake in clinical settings. Strategic partnerships with academic and clinical centers can both accelerate real-world validation and generate high-quality clinical evidence for new indications. Fourth, expand regional manufacturing and localized service footprints in a targeted way to mitigate tariff exposure and improve time to service in key markets. This should be balanced with rigorous supplier qualification to preserve quality standards.

Fifth, adopt flexible commercial models that combine hardware, reagent, and service contracts with outcome-based or subscription pricing where appropriate; this aligns incentives between suppliers and buyers and can lower barriers to adoption for new technologies. Finally, maintain an enterprise focus on regulatory agility and post-market surveillance, investing in robust quality systems and data management capabilities to support international approvals and long-term product trust. Collectively, these actions will position leaders to capitalize on clinical trends while managing operational and commercial risk.

A robust research approach combining technical literature, regulatory review, and expert interviews to triangulate instrument trends, supply chain responses, and competitive dynamics

The research underpinning this analysis combined a structured review of technical literature, regulatory guidance, industry filings, and primary qualitative interviews with subject matter experts across diagnostics, laboratory management, and procurement. Instrument performance characteristics and technology trends were cross-validated through technical white papers and peer-reviewed studies to ensure factual accuracy regarding assay modalities and analytic capabilities. Supply chain and tariff impacts were examined through trade data, company disclosures, and interviews with procurement leaders to capture both observed adjustments and strategic intent.

Segmentation and regional insights were developed by synthesizing device classifications, application profiles, and end-user requirements, informed by interviews with clinical laboratory directors, hospital procurement officers, and academic researchers. Competitive dynamics were assessed through public corporate filings, product launch histories, and analysis of service and partnership announcements. Wherever possible, findings were triangulated across multiple independent sources to reduce bias and increase confidence in the conclusions.

Finally, methodological rigor was applied to avoid speculative projections. The focus remained on observable trends, documented strategic responses, and validated technical capabilities. Limitations of the research are acknowledged, including the evolving nature of regulatory landscapes and the potential for rapid technological breakthroughs that may alter competitive dynamics over short timeframes. These caveats are addressed through recommended monitoring indicators that decision-makers can use to track material changes.

Synthesis of critical imperatives for manufacturers and buyers to align innovation, resilience, and clinical utility in the evolving diagnostics instrument landscape

The diagnostic instrument sector stands at a pivotal moment where technological innovation, shifting care models, and supply chain recalibration converge to redefine product and commercial priorities. Instrument manufacturers that succeed will be those that can marry compelling analytic performance with flexible deployment options, resilient supply chains, and digital-first service models. Healthcare providers and laboratory networks will increasingly reward partners that offer integrated solutions delivering reliability, interoperability, and demonstrable clinical utility.

Going forward, attention should remain fixed on how molecular and immunoassay advances are translated into workflow-friendly instruments, how digital connectivity enhances both clinical decision support and operational efficiency, and how regional strategies can be tailored to regulatory and infrastructure realities. The combined pressures of regulatory scrutiny, tariff variability, and customer demands for lower total cost of ownership necessitate strategic choices around platform architecture, manufacturing geography, and commercial models. By aligning product development with real-world clinical needs and by investing in localized service and compliance capabilities, stakeholders can create durable competitive advantages that support long-term growth and improved patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. In-Vitro Diagnostics Instrument Market, by Instrument Type

  • 8.1. Chemistry Analyzer
  • 8.2. Coagulation Analyzer
  • 8.3. Hematology Analyzer
  • 8.4. Immunoassay Analyzer
  • 8.5. Microbiology Analyzer
  • 8.6. Molecular Diagnostics
  • 8.7. Point Of Care

9. In-Vitro Diagnostics Instrument Market, by Technology

  • 9.1. Chromatography
    • 9.1.1. Affinity Chromatography
    • 9.1.2. Gas Chromatography
    • 9.1.3. Ion Exchange Chromatography
    • 9.1.4. Liquid Chromatography
  • 9.2. Cytometry
    • 9.2.1. Flow Cytometry
    • 9.2.2. Image Cytometry
  • 9.3. Immunoassay
    • 9.3.1. Chemiluminescence
    • 9.3.2. Enzyme Linked Immunosorbent Assay
    • 9.3.3. Fluorescence Immunoassay
    • 9.3.4. Turbidimetric Immunoassay
  • 9.4. Microscopy
    • 9.4.1. Confocal Microscopy
    • 9.4.2. Electron Microscopy
    • 9.4.3. Light Microscopy
  • 9.5. Molecular
    • 9.5.1. Hybridization
    • 9.5.2. Microarray
    • 9.5.3. Next Generation Sequencing
    • 9.5.4. Pcr
  • 9.6. Spectrometry
    • 9.6.1. Fluorescence Spectroscopy
    • 9.6.2. Mass Spectrometry
    • 9.6.3. Uv Visible Spectroscopy

10. In-Vitro Diagnostics Instrument Market, by Configuration

  • 10.1. Benchtop
  • 10.2. Floor Standing
  • 10.3. Handheld
  • 10.4. Portable

11. In-Vitro Diagnostics Instrument Market, by Application

  • 11.1. Autoimmune
  • 11.2. Cardiac Markers
  • 11.3. Diabetes
  • 11.4. Infectious Disease
  • 11.5. Oncology

12. In-Vitro Diagnostics Instrument Market, by End User

  • 12.1. Academic Research
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals

13. In-Vitro Diagnostics Instrument Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. In-Vitro Diagnostics Instrument Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. In-Vitro Diagnostics Instrument Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States In-Vitro Diagnostics Instrument Market

17. China In-Vitro Diagnostics Instrument Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Agilent Technologies, Inc.
  • 18.7. Becton, Dickinson and Company
  • 18.8. Bio-Rad Laboratories, Inc.
  • 18.9. BioMerieux S.A.
  • 18.10. Danaher Corporation
  • 18.11. EKF GmbH
  • 18.12. F. Hoffmann-La Roche Ltd
  • 18.13. Hologic, Inc.
  • 18.14. Illumina, Inc.
  • 18.15. Mesolonghi Diagnostics
  • 18.16. Ortho Clinical Diagnostics
  • 18.17. PerkinElmer, Inc.
  • 18.18. PHC Corporation
  • 18.19. Qiagen N.V.
  • 18.20. Roche Diagnostics
  • 18.21. Siemens Healthineers AG
  • 18.22. Sysmex Corporation
  • 18.23. Thermo Fisher Scientific Inc.
  • 18.24. Tulip Diagnostics (P) Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INSTRUMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CONFIGURATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CHEMISTRY ANALYZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CHEMISTRY ANALYZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CHEMISTRY ANALYZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY COAGULATION ANALYZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY COAGULATION ANALYZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY COAGULATION ANALYZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY HEMATOLOGY ANALYZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY HEMATOLOGY ANALYZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY HEMATOLOGY ANALYZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY IMMUNOASSAY ANALYZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY IMMUNOASSAY ANALYZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY IMMUNOASSAY ANALYZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MICROBIOLOGY ANALYZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MICROBIOLOGY ANALYZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MICROBIOLOGY ANALYZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY GAS CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY GAS CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY GAS CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY LIQUID CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY LIQUID CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY LIQUID CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY IMAGE CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY IMAGE CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY IMAGE CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CHEMILUMINESCENCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CHEMILUMINESCENCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CHEMILUMINESCENCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY TURBIDIMETRIC IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY TURBIDIMETRIC IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY TURBIDIMETRIC IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CONFOCAL MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CONFOCAL MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CONFOCAL MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY ELECTRON MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY ELECTRON MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY ELECTRON MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY LIGHT MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY LIGHT MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY LIGHT MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MOLECULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MOLECULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MOLECULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY FLUORESCENCE SPECTROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY FLUORESCENCE SPECTROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY FLUORESCENCE SPECTROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY UV VISIBLE SPECTROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY UV VISIBLE SPECTROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY UV VISIBLE SPECTROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY BENCHTOP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY BENCHTOP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY BENCHTOP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY FLOOR STANDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY FLOOR STANDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY FLOOR STANDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY HANDHELD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY HANDHELD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY HANDHELD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PORTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PORTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PORTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CARDIAC MARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CARDIAC MARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CARDIAC MARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY ACADEMIC RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY ACADEMIC RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. GCC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. GCC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. GCC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 261. GCC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 262. GCC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 263. GCC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 264. GCC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 265. GCC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 266. GCC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 267. GCC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 268. GCC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. GCC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 290. BRICS IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS IN-VITRO DIAGNOST